COVID-19 Vaccination Requirement
All in-person attendees must be fully vaccinated.

Vaccine Requirement

The safety of meeting attendees is ASGCT’s top priority and we believe the most effective way to ensure that safety is for everyone to be vaccinated against COVID-19. Please note that proof of vaccination will be required for all in-person meeting attendees prior to traveling to Washington, D.C. 

We define “fully vaccinated” to be:

  • At least 14 days past the final administration of the second dose in a two-dose series (i.e. Pfizer or Moderna vaccines),


  • At least 14 days past a single-dose administration (i.e. Johnson & Johnson vaccine)

ASGCT will accept a full course of immunization with any vaccine that has been authorized by the World Health Organization (WHO) or the U.S. Food and Drug Administration (FDA). The product may be either fully authorized or authorized under an Emergency Use Authorization (EUA) or equivalent at the time of travel (see list of eligible vaccines). Vaccination with an agent that is not included on the WHO or FDA website as authorized will not be accepted. 

See List of Eligible Vaccines

Booster shots are not required, but are recommended for any eligible communities. For those unable to travel or meet the vaccination requirement, ASGCT is offering a virtual registration option. 

Please check back to this page for updates, which we will add as they are confirmed.


Prior to arriving on site, attendees will be asked to provide proof that they are fully vaccinated with a vaccine approved by the WHO or FDA. ASGCT will be contracting with a third-party vendor to manage the verification process. More details will be provided on this process as they become available.

COVID-19 Testing

ASGCT is not able to offer onsite COVID-19 testing but there are nearby testing centers available. Please visit the Washington, D.C. COVID-19 website for more information on testing sites.

If onsite attendees become symptomatic they must immediately get tested for COVID-19 and cease participation in the meeting and all related events and notify as soon as possible. Individuals who test positive will not be permitted to continue attending the meeting in person and must follow CDC guidance on quarantine and isolation.

Individuals who test negative will be permitted to participate in the meeting again if they present the negative test results to the Help Desk located in the registration area.

International Attendees

International attendees should always check current travel restrictions to the U.S. on the CDC website before planning travel arrangements. In addition, please monitor regulations in your home country to ensure that you will be able to return from the U.S.

Other Guidelines

Anyone experiencing symptoms of COVID-19 must refrain from attending the meeting. The CDC states the symptoms of COVID-19 include: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headaches, new loss of taste or smell, sore throat, congestion or running nose, nausea or vomiting, diarrhea, or a fever (100.4º F or higher). As a reminder, all registered attendees will have access to view the event virtually.

If you are attending in person and you experience any COVID-19 symptoms, please refrain from attending and notify as soon as possible.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.